Derma E is joining the Topix family of brands. Topix Pharmaceuticals, a provider of micro-branded and branded skincare products, has announced its acquisition of the natural skincare brand. The partnership will provide the vegan skincare brand with additional resources to support its growth while expanding the Topix portfolio of brands, and furthering the Topix commitment of entering the natural skincare category.
“We are thrilled to welcome Derma E into the Topix family,” said Andre Moura, managing director at New Mountain Capital and chairman of the Topix board of directors. “Topix is a leader in the dermatologist market with differentiated innovation and FDA-certified manufacturing capabilities. We look forward to supporting Derma E and its customers with these resources, and believe the partnership will create multiple new avenues of long-term growth for both Derma E and the broader Topix business.”
Following the acquisition, Derma E will continue to operate in Simi Valley, CA, and will continue to develop its collection of clinically supported and cruelty-free skincare products. Over the last 35 years, Derma E has been growing as a trailblazing name in the eco-ethical skincare industry.
“Topix is an ideal partner to help Derma E not only accelerate its growth plans but also ensure that the integrity of the brand and its mission remain,” says David Stearn, cofounder and CEO of Derma E. “Topix is highly regarded amongst dermatologists as a leader in innovative and clinically-validated skincare products and we believe several new opportunities can be opened for Derma E as a result of this transaction.”
Topix is backed by New Mountain Capital, a growth-oriented investment firm that currently manages more than $20 billion in assets. New Mountain Capital invested in Topix in July 2016 to provide equity capital for Topix to execute a growth strategy, including both organic and acquisition-led growth.